These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 16614245)
1. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Breit S; Stanulla M; Flohr T; Schrappe M; Ludwig WD; Tolle G; Happich M; Muckenthaler MU; Kulozik AE Blood; 2006 Aug; 108(4):1151-7. PubMed ID: 16614245 [TBL] [Abstract][Full Text] [Related]
2. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Jenkinson S; Koo K; Mansour MR; Goulden N; Vora A; Mitchell C; Wade R; Richards S; Hancock J; Moorman AV; Linch DC; Gale RE Leukemia; 2013 Jan; 27(1):41-7. PubMed ID: 22814294 [TBL] [Abstract][Full Text] [Related]
3. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120 [TBL] [Abstract][Full Text] [Related]
4. NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China. Gao C; Liu SG; Zhang RD; Li WJ; Zhao XX; Cui L; Wu MY; Zheng HY; Li ZG Br J Haematol; 2014 Jul; 166(2):221-8. PubMed ID: 24690100 [TBL] [Abstract][Full Text] [Related]
5. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721 [TBL] [Abstract][Full Text] [Related]
6. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Bandapalli OR; Zimmermann M; Kox C; Stanulla M; Schrappe M; Ludwig WD; Koehler R; Muckenthaler MU; Kulozik AE Haematologica; 2013 Jun; 98(6):928-36. PubMed ID: 23349303 [TBL] [Abstract][Full Text] [Related]
7. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387 [TBL] [Abstract][Full Text] [Related]
8. miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. Piatopoulou D; Avgeris M; Marmarinos A; Xagorari M; Baka M; Doganis D; Kossiva L; Scorilas A; Gourgiotis D Br J Cancer; 2017 Sep; 117(6):801-812. PubMed ID: 28787435 [TBL] [Abstract][Full Text] [Related]
9. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134 [TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series. Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942 [No Abstract] [Full Text] [Related]
11. High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group. Reismüller B; Steiner M; Pichler H; Dworzak M; Urban C; Meister B; Schmitt K; Pötschger U; König M; Mann G; Haas OA; Attarbaschi A; Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27804199 [TBL] [Abstract][Full Text] [Related]
12. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol. Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood. Schmäh J; Fedders B; Panzer-Grümayer R; Fischer S; Zimmermann M; Dagdan E; Bens S; Schewe D; Moericke A; Alten J; Bleckmann K; Siebert R; Schrappe M; Stanulla M; Cario G Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28371317 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95. Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312 [No Abstract] [Full Text] [Related]
15. Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia. Valliyammai N; Nancy NK; Sagar TG; Rajkumar T J Pediatr Hematol Oncol; 2018 Jan; 40(1):e1-e8. PubMed ID: 29200162 [TBL] [Abstract][Full Text] [Related]
16. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Zuurbier L; Homminga I; Calvert V; te Winkel ML; Buijs-Gladdines JG; Kooi C; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Petricoin EF; Pieters R; Meijerink JP Leukemia; 2010 Dec; 24(12):2014-22. PubMed ID: 20861909 [TBL] [Abstract][Full Text] [Related]
17. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Kox C; Zimmermann M; Stanulla M; Leible S; Schrappe M; Ludwig WD; Koehler R; Tolle G; Bandapalli OR; Breit S; Muckenthaler MU; Kulozik AE Leukemia; 2010 Dec; 24(12):2005-13. PubMed ID: 20944675 [TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891 [TBL] [Abstract][Full Text] [Related]
19. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia. Lauten M; Cario G; Asgedom G; Welte K; Schrappe M Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754 [TBL] [Abstract][Full Text] [Related]
20. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]